Use of patent term extensions to restore regulatory time for medical devices in the United States

References

• Besen SM, Raskind LJ. An introduction to the law and economics of intellectual property. J Econ Perspect. [1991 Feb 1];5(1):3–27. doi: 10.1257/jep.5.1.3
   Web of Science ®Google Scholar
• Scherer FM. The pharmaceutical industry. Handb Health Econ. [2000 Jan 1];1:1297–1336. doi: 10.1016/S1574-0064(00)80038-4
   Google Scholar
• Pub. L. No. 98-417, 98 Stat. 1585 https://uscode.house.gov/statutes/pl/98/417.pdf (1984).
   Google Scholar
• Pub. L. No. 100–670, 102 Stat. 3971. https://uscode.house.gov/statutes/pl/100/670.pdf(1988)
   Google Scholar
• Boone JS. Patent term extensions for human drugs under the US Hatch–Waxman Act. JIPLP. [2009 Sep 1];4(9):658–664. doi: 10.1093/jiplp/jpp110
   Google Scholar
• Ouellette LL. How many patents does it take to make a drug-follow-on pharmaceutical patents and university licensing. Mich Telecomm & Tech L Rev. 2010;17:299. Available from: https://heinonline.org/HOL/P?h=hein.journals/mttlr17&i=301
   Google Scholar
• Sawad AB, Alshahrani AM, Seoane-Vazquez E, et al. Analysis of the Waxman-Hatch Act pharmaceutical patent extensions. Value Health. 1984–2012 [2013 May 1];16(3):A245. doi: 10.1016/j.jval.2013.03.1249
   Google Scholar
• Schacht WH, Thomas JR. Pharmaceutical patent term extensions: a brief explanation. CRS, LOC. [2002 Jan 31] Order Code RS21129. https://www.policyarchive.org/download/3565
   Google Scholar
• Grabowski H, Vernon J. Longer patents for lower imitation barriers: The 1984 Drug Act. Am Econ Rev. [1986 May 1];76(2):195–198. Available from: https://www.jstor.org/stable/1818763
   Web of Science ®Google Scholar
• U.S. Code 35 § 156. 2011. https://www.govinfo.gov/app/details/USCODE-2011-title35/USCODE-2011-title35-partII-chap14-sec156
   Google Scholar
• Clift C. The value of patent term extensions to the pharmaceutical industry in the USA. J Generic Med. 2008 Apr;5(3):201–208. doi: 10.1057/jgm.2008.6
   Google Scholar
• Beall RF, Darrow JJ, Kesselheim AS. Patent term restoration for top-selling drugs in the United States. Drug Discovery Today. [2019 Jan 1];24(1):20–25. doi: 10.1016/j.drudis.2018.07.006
   PubMed Web of Science ®Google Scholar
• Rome BN, Lee CC, Kesselheim AS. Market exclusivity length for drugs with new generic or biosimilar competition, 2012–2018. Clinical Pharmacology & Therapeutics. 2021 Feb;109(2):367–371. doi: 10.1002/cpt.1983
   PubMed Web of Science ®Google Scholar
• Alhiary R, Kesselheim AS, Gabriele S, et al. Patents and regulatory exclusivities on GLP-1 receptor agonists. JAMA. [2023 Aug 15];330(7):650–657. doi: 10.1001/jama.2023.13872
   PubMed Web of Science ®Google Scholar
• Sadick A. The dispute of the patent term extension in Australia. JIPLP. [2019 Sep 1];14(9):699–715. doi: 10.1093/jiplp/jpz081
   Google Scholar
• Sampat BN, Shadlen KC. TRIPS implementation and secondary pharmaceutical patenting in Brazil and India. St Comp Int Dev. 2015 Jun;50(2):228–257. doi: 10.1007/s12116-015-9181-7
   Web of Science ®Google Scholar
• Tenni B, Moir HV, Townsend B, et al. What is the impact of intellectual property rules on access to medicines? A systematic review. Globalization Health. [2022 Apr 15];18(1):40. doi: 10.1186/s12992-022-00826-4
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Kano S. Patent term extension systems differentiate Japanese and US drug lifecycle management. Drug Discovery Today. [2016 Jan 1];21(1):111–117. doi: 10.1016/j.drudis.2015.09.005
   PubMed Web of Science ®Google Scholar
• Cook T. The court of justice recasts the EU patent term extension system. Journal Of Intellectual Property Rights (JIPR). [2023 Mar 4];19(2):141–145. doi: 10.56042/jipr.v19i2.5144
   Google Scholar
• Lietzan E, Acri KM, Weidner E. The case of the missing device patents, or: why device patents matter. Fordham Intell Prop Media & Ent LJ. 2022;33:409. Available from: https://heinonline.org/HOL/P?h=hein.journals/frdipm33&i=421
   Google Scholar
• Lewin A. Medical device innovation in America: tensions between food and drug law and patent law. Harv JL & Tech. 2012;26:403. Available from: https://heinonline.org/HOL/P?h=hein.journals/hjlt26&i=409
   Google Scholar
• Applications for patent term extension and patent terms extended under 35 U.S.C. § 156. [Internet]. Alexandria (VA): USPTO; [cited 2024 Jan 2]. Available from: https://www.uspto.gov/patents/laws/patent-term-extension/patent-terms-extended-under-35-usc-156
   Google Scholar
• IBM Corp. 2021. IBM SPSS statistics for windows, version 28.0. Armonk (NY): IBM Corp; Available from: https://hadoop.apache.org
   Google Scholar
• Grabowski H, Vernon J. Longer patents for increased generic competition in the US: the Waxman-Hatch Act after one decade. PharmacoEconomics. 1996 Dec;10(Supplement 2):110–123. doi: 10.2165/00019053-199600102-00017
   PubMed Web of Science ®Google Scholar
• Van de Wiele VL, Kesselheim AS, Nagar S, et al. The prevalence of drug patent term extensions in the United States, 2000–2018. Nat Biotechnol. 2023 Jul;41(7):903–906. doi: 10.1038/s41587-023-01847-z
   PubMed Web of Science ®Google Scholar
• Singh A, Triulzi G, Magee CL. Technological improvement rate predictions for all technologies: Use of patent data and an extended domain description. Res Policy. [2021 Nov 1];50(9):104294. doi: 10.1016/j.respol.2021.104294
   Web of Science ®Google Scholar
• Caughron H, Dhruva SS. Medical device modifications through premarket approval supplements—ensuring patient safety. JAMA Netw Open. 2023;6(4):e237704. doi: 10.1001/jamanetworkopen.2023.7704
   PubMed Web of Science ®Google Scholar
• Sherwood MA. Medical devices and patent term extension under the hatch-waxman act. Landslide. 2009;2:39. Available from: https://heinonline.org/HOL/P?h=hein.journals/lndslid2&i=381
   Google Scholar
• Wall J, Gurtner GC, Longaker MT. From idea to bedside: the process of surgical invention and innovation. Key Topics In Surgical Research And Methodology. 2010:647–656. doi: 10.1007/978-3-540-71915-1_52
   Google Scholar
• Aboy M, Crespo C, Stern A. Beyond the 510 (k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA’s De Novo pathway. npj Digital Med. [2024 Feb 8];7(1):29. doi: 10.1038/s41746-024-01021-y
   PubMed Web of Science ®Google Scholar
• Sertkaya A, DeVries R, Jessup A, et al. Estimated cost of developing a therapeutic complex medical device in the US. JAMA Netw Open. 2022;5(9):e2231609. doi: 10.1001/jamanetworkopen.2022.31609
   PubMed Web of Science ®Google Scholar
• Bhat VN. Patent term extension strategies in the pharmaceutical industry. Pharmaceuticals Policy And Law. [2005 Jan 1];6:109–122.
   Google Scholar
• Allison JR, Lemley MA. The growing complexity of the United States patent system. BUL Rev. 2002;82:77. Available from: https://heinonline.org/HOL/P?h=hein.journals/bulr82&i=89
   Google Scholar
• Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. JControlled Release. [1995 Jul 1];35(1):1–21. doi: 10.1016/0168-3659(95)00013-X
   Web of Science ®Google Scholar
• Beall RF, Nickerson JW, Kaplan WA, et al. Is patent “evergreening” restricting access to medicine/device combination products? PLOS ONE. [2016 Feb 24];11(2):e0148939. doi: 10.1371/journal.pone.0148939
   PubMed Web of Science ®Google Scholar
• Jee SJ, Sohn SY. Patent network based conjoint analysis for wearable device. Technol Forecasting Social Change. [2015 Dec 1];101:338–346. doi: 10.1016/j.techfore.2015.09.018
   Web of Science ®Google Scholar